Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis?

Clinics and Research in Hepatology and Gastroenterology

Volumn 35, Issue 6-7, 2011, Pages 455-464

  Vezali, Elena ^a,b   Aghemo, Alessio ^a   Lampertico, Pietro ^a   Colombo, Massimo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b HYGEIA HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; AFLATOXIN; ALANINE AMINOTRANSFERASE; ALCOHOL; ALPHA INTERFERON; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NUCLEOSIDE DERIVATIVE; PEGINTERFERON ALPHA; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN; VIRUS DNA;

ADVANCED CANCER; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL ABUSE; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL THERAPY; APOPTOSIS; ARTIFICIAL EMBOLISM; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CIGARETTE SMOKING; CONCURRENT INFECTION; DECOMPENSATED LIVER CIRRHOSIS; DELTA AGENT HEPATITIS; DISEASE ASSOCIATION; DISEASE COURSE; DOWN REGULATION; DRUG EFFICACY; DRUG RESPONSE; ERADICATION THERAPY; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LOW DRUG DOSE; MAINTENANCE THERAPY; MONOTHERAPY; PRIMARY PREVENTION; PROTEIN EXPRESSION; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; REMISSION; RISK REDUCTION; SEROCONVERSION; SEX DIFFERENCE; SHORT SURVEY; SUSTAINED VIROLOGICAL RESPONSE; TUMOR ABLATION; VACCINATION; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

EID: 80052309181     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2011.02.008     Document Type: Short Survey

References (76)

1. Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127(5 Suppl 1):S5-16.
2. International Agency for Cancer Reseach. Liver Cancer Incidence and Mortality Worldwide. GLOBOCAN 2008: http://globocan.iarc.fr/factsheets/cancers/liver.asp. Last accessed on 03 of November 2010.
3. Bosch FX, Ribes J, Cléries R, Díaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005;9(2):191-211.
4. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004;127(5 Suppl 1):S27-34.
5. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127(5 Suppl 1):S35-50.
6. Benvegnù L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004;53(5):744-9.
7. Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 2006;43(6):1303-10.
8. Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, Omata M, et al. World Gastroenterology Organisation Guideline. Hepatocellular carcinoma (HCC): a global perspective. J Gastrointestin Liver Dis 2010;19(3):311-7.
9. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336(26):1855-9.
10. Ghany MG, Strader DB, Thomas DL, Seeff LB. American Association for the Study of the Liver Disease. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49(4):1335-74.
11. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-42.
12. Lok AS, McMahon BJ. American Association for the Study of Liver Disease Practice Guidelines. Chronic hepatitis B: Update 2009. Available at http://www.aasld.org/practiceguidelines/Pages/NewUpdatedGuidelines.aspx.(last accessed on 13 of January 2011).
13. Chevaliez S, Pawlotsky JM. Interferon-based therapy of hepatitis C. Adv Drug Deliv Rev 2007;59(12):1222-41.
14. Ferrantini M, Capone I, Belardelli F. Interferon-a and cancer: mechanisms of action and new perspectives of clinical use. Biochimie 2007;89:884-93.
15. Chawla-Sarkar M, Lindner D, Liu Y, Williams B, Sen G, Silverman R, et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003;8:237-49.
16. Donato MF, Degott C, Arosio E, Martinot M, Monti V, Morabito A, et al. Interferon-alpha suppresses liver cell proliferation in patients with chronic hepatitis C virus infection. J Viral Hepat 2005;12(5):499-506.
17. Hepatitis C fact sheet. Geneva: World Health Organization. http://www.who.int/mediacentre/factsheets/fs164/en/. Last accessed on 03 of December 2010.
18. Global Burden of Hepatitis C. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004;44(1):20-29.
19. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-72.
20. Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis 2005;9:383-98.
21. Asahina Y, Tsuchiya K, Tamaki N, Hirayama I, Tanaka T, Sato M, et al. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology 2010;52(2):518-27.
22. Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A, et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002;155(4):323-31.
23. John-Baptiste AA, Tomlinson G, Hsu PC, Krajden M, Heathcote EJ, Laporte A, et al. Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C. Am J Gastroenterol 2009;104(10):2248-439.
24. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358(9286):958-65.
25. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales Jr FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347(13):975-82.
26. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. For the IDEAL Study Team. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361(6):580-93.
27. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomized trial of effect of interferon-a on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-5.
28. Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S, Inada M, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C osaka hepatocellular carcinoma prevention study group. Ann Intern Med 1998;129(2):94-9.
29. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999;29(4):1124-30.
30. Tanaka H, Tsukuma H, Kasahara A, Hayashi N, Yoshihara H, Masuzawa M, et al. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000;87(5):741-9.
31. Papatheodoridis GV, Papadimitropoulos VC, Hadziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment Pharmacol Ther 2001;15(5):689-98.
32. Cammà C, Giunta M, Andreone P, Craxì A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001;34(4):593-602.
33. Craxì A, Cammà G. Prevention of hepatocellular carcinoma. Clin Liver Dis 2005;9:329-46.
34. Yoshida H, Tatesi R, Arakawa Y. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut 2004;53:425-30.
35. Shiratori Y, Ito Y, Yokosuka O, Imazeki F, Nakata R, Tanaka N, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005;142(2):105-14.
36. Hung CH, Lee CM, Lu SN, Wang JH, Hu TH, Tung HD, et al. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. J Viral Hepat 2006;13(6):409-14.
37. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnù L, Mazzella G, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007;45(3):579-87.
38. Cardoso AC, Moucari R, Figueiredo-Mendes C, Ripault MP, Giuily N, Castelnau C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010;52(5):652-7.
39. Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010;52(3):833-44.
40. Alazawi W, Cunningham M, Dearden J, Foster GR. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther 2010;32(3):344-55.
41. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. AASLD practice guidelines. Available at http://www.aasld.org/practiceguidelines/Pages/NewUpdatedGuidelines.aspx. Last accessed on 02 of December, 2010.
42. Mallet V, Gilgenkrantz H, Serpaggi J, Verkarre V, Vallet-Pichard A, Fontaine H, et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008;149(6):399-403.
43. Aghemo A, Colombo M. Cirrhosis regression in chronic hepatitis C: an old tale with a new ending. Gastroenterology 2009;136(4):1447-9.
44. Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, et al. HALT-C trial investigators. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008;359(23):2429-41.
45. Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, et al. Epic study group. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009;136(5):1618-28.
46. Afdhal NH, Levine R, Brown Jr B, Freilich B, O'Brien M, Brass C. Colchicine versus PEG-interferon alfa-2b long-term therapy: results of the 4-year COPILOT trial. J Hepatol 2008;48(Suppl. 2):S4 (Abstract 3).
47. Lok A, Everhart J, Wright E, Di Bisceglie A, Kim H, Sterling R. For the HALT-C Trial Group. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 2011;140(3):840-9.
48. Cammà C, Di Marco V, Orlando A, Sandonato L, Casaril A, Parisi P, et al. Unità Interdipartimentale Neoplasie Epatiche (U.I.N.E) Group Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study. J Hepatol 2005;42(4):535-40.
49. Lencioni RA, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003;228(1):235-40.
50. Shen YC, Hsu C, Chen LT, Cheng CC, Hu FC, Cheng AL. Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach. J Hepatol 2010;52:889-94.
51. Hung CH, Lee CM, Wang JH, Tung HD, Chen CH, Lu SN. Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus. J Gastroenterol Hepatol 2005;20(10):1553-9.
52. Sakaguchi Y, Kudo M, Fukunaga T, Minami Y, Chung H, Kawasaki T. Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma. Intervirology 2005;48(1):64-70.
53. Nishiguchi S, Tamori A, Kubo S. Effect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma. Intervirology 2005;48(1):71-5.
54. Chu CM, Liaw YF. Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis 2006;26(2):142-52.
55. Chen YC, Chu CM, Yeh CT, Liaw YF. Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study. Hepatol Int 2007;1(1):267-73.
56. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
57. Liaw YF, Brunetto MR, Hadzyyannis S. The natural history of hepatits B virus infection and gegraphical differences. Antiviral Therapy 2010;15(Suppl. 3):25-33.
58. Chen CJ, Yu MW, Liaw YF. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol 1997;12:S294-308.
59. Ming L, Thorgeirsson SS, Gail MH, Lu P, Harris CC, Wang N, et al. Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong China. Hepatology 2002;36(5):1214-20.
60. Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009;101:1348-55.
61. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010;53(2):348-56.
62. Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008;28(9):1067-77.
63. Yang YF, Zhao W, Zhong YD, Xia HM, Shen L, Zhang N. Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. J Viral Hepat 2009;16(4):265-71.
64. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, Häussinger D. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334(22):1422-7.
65. Lin SM, Yu ML, Lee CM, Chien RN, Sheen IS, Chu CM, Liaw YF. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007;46(1):45-52.
66. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001;34(2):306-13.
67. Brunetto MR, Oliveri F, Coco B, Leandro G, Colombatto P, Gorin JM, Bonino F. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002;36(2):263-70.
68. Lampertico P, Del Ninno E, Viganò M, Romeo R, Donato MF, Sablon E, et al. Long-term suppression of hepatitis B e antigennegative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003;37(4):756-63.
69. Fattovich G, Giustina G, Sanchez-Tapias J, et al. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European concerted action on viral hepatitis (EUROHEP). Am J Gastroenterol 1998;93(6):896-900.
70. Feld JJ, Wong DK, Heathcote EJ. Endpoints of therapy in chronic hepatitis B. Hepatology (Baltimore) 2009;49(5 Suppl):S96-102.
71. Yuen MF, Wong DK, Sablon E, Tse E, Ng IO, Yuan HJ. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology 2004;39(6):1694-701.
72. Simonetti J, Bulkow L, McMahon BJ, Homan C, Snowball M, Negus S, et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 2010;51(5):1531-7.
73. Sun HC, Tang ZY, Wang L, Qin LX, Ma ZC, Ye QH, et al. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol 2006;132(7):458-65.
74. Someya T, Ikeda K, Saitoh S, Kobayashi M, Hosaka T, Sezaki H, et al. Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus-related cirrhosis. J Gastroenterol 2006;41(12):1206-13.
75. Lo CM, Liu CL, Chan SC, Lam CM, Poon RT, Ng IO, et al. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 2007;245(6):831-42.
76. Qu LS, Jin F, Huang XW, Shen XZ. Interferon-α therapy after curative resection prevents early recurrence and improves survival in patients with hepatitis B virus-related hepatocellular carcinoma. J Surg Oncol 2010;102(7):796-801.